204 related articles for article (PubMed ID: 28862809)
1. Novel luciferase-opsin combinations for improved luminopsins.
Park SY; Song SH; Palmateer B; Pal A; Petersen ED; Shall GP; Welchko RM; Ibata K; Miyawaki A; Augustine GJ; Hochgeschwender U
J Neurosci Res; 2020 Mar; 98(3):410-421. PubMed ID: 28862809
[TBL] [Abstract][Full Text] [Related]
2. Step-function luminopsins for bimodal prolonged neuromodulation.
Berglund K; Fernandez AM; Gutekunst CN; Hochgeschwender U; Gross RE
J Neurosci Res; 2020 Mar; 98(3):422-436. PubMed ID: 30957296
[TBL] [Abstract][Full Text] [Related]
3. Luminopsins integrate opto- and chemogenetics by using physical and biological light sources for opsin activation.
Berglund K; Clissold K; Li HE; Wen L; Park SY; Gleixner J; Klein ME; Lu D; Barter JW; Rossi MA; Augustine GJ; Yin HH; Hochgeschwender U
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E358-67. PubMed ID: 26733686
[TBL] [Abstract][Full Text] [Related]
4. Light-emitting channelrhodopsins for combined optogenetic and chemical-genetic control of neurons.
Berglund K; Birkner E; Augustine GJ; Hochgeschwender U
PLoS One; 2013; 8(3):e59759. PubMed ID: 23544095
[TBL] [Abstract][Full Text] [Related]
5. Defining parameters of specificity for bioluminescent optogenetic activation of neurons using in vitro multi electrode arrays (MEA).
Prakash M; Medendorp WE; Hochgeschwender U
J Neurosci Res; 2020 Mar; 98(3):437-447. PubMed ID: 30152529
[TBL] [Abstract][Full Text] [Related]
6. Improved Locomotor Recovery in a Rat Model of Spinal Cord Injury by BioLuminescent-OptoGenetic (BL-OG) Stimulation with an Enhanced Luminopsin.
Ikefuama EC; Kendziorski GE; Anderson K; Shafau L; Prakash M; Hochgeschwender U; Petersen ED
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361784
[TBL] [Abstract][Full Text] [Related]
7. Combined Optogenetic and Chemogenetic Control of Neurons.
Berglund K; Tung JK; Higashikubo B; Gross RE; Moore CI; Hochgeschwender U
Methods Mol Biol; 2016; 1408():207-25. PubMed ID: 26965125
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive activation of optogenetic actuators.
Birkner E; Berglund K; Klein ME; Augustine GJ; Hochgeschwender U
Proc SPIE Int Soc Opt Eng; 2014 Feb; 8928():. PubMed ID: 27965518
[TBL] [Abstract][Full Text] [Related]
9. The BioLuminescent-OptoGenetic in vivo response to coelenterazine is proportional, sensitive, and specific in neocortex.
Gomez-Ramirez M; More AI; Friedman NG; Hochgeschwender U; Moore CI
J Neurosci Res; 2020 Mar; 98(3):471-480. PubMed ID: 31544973
[TBL] [Abstract][Full Text] [Related]
10. Extending the Time Domain of Neuronal Silencing with Cryptophyte Anion Channelrhodopsins.
Govorunova EG; Sineshchekov OA; Hemmati R; Janz R; Morelle O; Melkonian M; Wong GK; Spudich JL
eNeuro; 2018; 5(3):. PubMed ID: 30027111
[TBL] [Abstract][Full Text] [Related]
11. Bioluminescence-Optogenetics: A Practical Guide.
Stern MA; Skelton H; Fernandez AM; Gutekunst CN; Berglund K; Gross RE
Methods Mol Biol; 2022; 2525():333-346. PubMed ID: 35836081
[TBL] [Abstract][Full Text] [Related]
12. The Expanding Family of Natural Anion Channelrhodopsins Reveals Large Variations in Kinetics, Conductance, and Spectral Sensitivity.
Govorunova EG; Sineshchekov OA; Rodarte EM; Janz R; Morelle O; Melkonian M; Wong GK; Spudich JL
Sci Rep; 2017 Mar; 7():43358. PubMed ID: 28256618
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory luminopsins: genetically-encoded bioluminescent opsins for versatile, scalable, and hardware-independent optogenetic inhibition.
Tung JK; Gutekunst CA; Gross RE
Sci Rep; 2015 Sep; 5():14366. PubMed ID: 26399324
[TBL] [Abstract][Full Text] [Related]
14. Structural foundations of optogenetics: Determinants of channelrhodopsin ion selectivity.
Berndt A; Lee SY; Wietek J; Ramakrishnan C; Steinberg EE; Rashid AJ; Kim H; Park S; Santoro A; Frankland PW; Iyer SM; Pak S; Ährlund-Richter S; Delp SL; Malenka RC; Josselyn SA; Carlén M; Hegemann P; Deisseroth K
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):822-9. PubMed ID: 26699459
[TBL] [Abstract][Full Text] [Related]
15. Improved trafficking and expression of luminopsins for more efficient optical and pharmacological control of neuronal activity.
Zhang JY; Tung JK; Wang Z; Yu SP; Gross RE; Wei L; Berglund K
J Neurosci Res; 2020 Mar; 98(3):481-490. PubMed ID: 31670406
[TBL] [Abstract][Full Text] [Related]
16. High-efficiency optogenetic silencing with soma-targeted anion-conducting channelrhodopsins.
Mahn M; Gibor L; Patil P; Cohen-Kashi Malina K; Oring S; Printz Y; Levy R; Lampl I; Yizhar O
Nat Commun; 2018 Oct; 9(1):4125. PubMed ID: 30297821
[TBL] [Abstract][Full Text] [Related]
17. Bioluminescence-Optogenetics.
Berglund K; Stern MA; Gross RE
Adv Exp Med Biol; 2021; 1293():281-293. PubMed ID: 33398820
[TBL] [Abstract][Full Text] [Related]
18. Machine learning-guided channelrhodopsin engineering enables minimally invasive optogenetics.
Bedbrook CN; Yang KK; Robinson JE; Mackey ED; Gradinaru V; Arnold FH
Nat Methods; 2019 Nov; 16(11):1176-1184. PubMed ID: 31611694
[TBL] [Abstract][Full Text] [Related]
19. Silencing Neurons: Tools, Applications, and Experimental Constraints.
Wiegert JS; Mahn M; Prigge M; Printz Y; Yizhar O
Neuron; 2017 Aug; 95(3):504-529. PubMed ID: 28772120
[TBL] [Abstract][Full Text] [Related]
20. Efficient opto- and chemogenetic control in a single molecule driven by FRET-modified bioluminescence.
Björefeldt A; Murphy J; Crespo EL; Lambert GG; Prakash M; Ikefuama EC; Friedman N; Brown TM; Lipscombe D; Moore CI; Hochgeschwender U; Shaner NC
Neurophotonics; 2024 Apr; 11(2):021005. PubMed ID: 38450294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
